Mainz Biomed N.V. (QUCY:NASDAQ) closed at $1.01 on October 23, 2026, down 0.98% on the day. The stock trades 79.5% below its 52-week high of $4.93 and 236.7% above its 52-week low of $0.300. Over the past year, it lost 36.5%. Mainz Biomed N.V. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, QUCY closed higher on 93 days (37%). Its best day was May 13, 2026 (+314.86%) and its worst was October 12, 2026 (-23.70%). The stock moved 10% or more in a single session 32 times. It opened at least 5% above the previous day's high 5 times.
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples.
Find more stocks like QUCY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.